CAJ | 학술논문

病毒感染是异基因造血干细胞移植(allo-HSCT)后常见的并发症,是影响患者长期生存的重要因素.由于细胞毒性T淋巴细胞(CTL)能识别病毒表面抗原,且具有HLA限制性,近来T细胞免疫治疗被用于防治移植后巨细胞病毒(CMV)、EB病毒(EBV)、腺病毒(AdV)等感染.文章就CTL治疗allo-HSCT后病毒感染的研究进展作一总结.
병독감염시이기인조혈간세포이식(allo-HSCT)후상견적병발증,시영향환자장기생존적중요인소.유우세포독성T림파세포(CTL)능식별병독표면항원,차구유HLA한제성,근래T세포면역치료피용우방치이식후거세포병독(CMV)、EB병독(EBV)、선병독(AdV)등감염.문장취CTL치료allo-HSCT후병독감염적연구진전작일총결.
Viral infections remain the common cause of morbidity and mortality in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).Virus antigens can be recognized by cytotoxic T-lymphocytes (CTL) in the context of HLA class Ⅰ molecules.T-cell-based immunotherapies are now being included in the clinical practice of transplant recipients to prevent and treat viral infections and complications associated with CMV,AdV and EBV.Here,the current status and future feasibility of CTL immunotherapy for virus infections after allo-HSCT are discussed.